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Suppression of splicingPre-mRNAsplicing of Pol II transcripts is executed in themammalian cell nucleuswithin a huge (21MDa) andhighly
dynamic RNP machine— the supraspliceosome. It is composed of four splicing active native spliceosomes, each re-
sembling an in vitro assembled spliceosome,which are connected by thepre-mRNA. Supraspliceosomes harbor pro-
tein splicing factors and all the ﬁve-spliceosomal U snRNPs. Recent analysis of speciﬁc supraspliceosomes at deﬁned
splicing stages revealed that theyharbor allﬁve spliceosomalU snRNAs at all splicing stages. Supraspliceosomes har-
bor additional pre-mRNA processing components, such as the 5′-end and 3′-end processing components, and the
RNA editing enzymes ADAR1 and ADAR2. The structure of the native spliceosome, at a resolution of 20 Å, was de-
termined by cryo-EM. A unique spatial arrangement of the spliceosomal U snRNPs within the native spliceosome
emerged from in-silico studies, localizing theﬁveU snRNPsmostlywithin its large subunit, and sheltering the active
core components deep within the spliceosomal cavity. The supraspliceosome provides a platform for coordinating
the numerous processing steps that the pre-mRNAundergoes: 5′ and 3′-end processing activities, RNA editing, con-
stitutive and alternative splicing, and processing of intronic microRNAs. It also harbors a quality control mechanism
termed suppression of splicing (SOS) that, under normal growth conditions, suppresses splicing at abundant
intronic latent 5′ splice sites in a reading frame-dependent fashion. Notably, changes in these regulatory processing
activities are associatedwith human disease and cancer. These ﬁndings emphasize the supraspliceosome as amulti-
task master regulator of pre-mRNA processing in the cell nucleus.
© 2014 Shefer et al. Published by Elsevier B.V. on behalf of the ResearchNetwork of Computational and Structural
Biotechnology. This is an open access article under the CC BY license
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Table 1
Proteins associated with supraspliceosomes.
Protein Cells origin References
snRNP proteins Syrian Hamster; HeLa;
TD40
[17,18,94]
hnRNP proteins Syrian Hamster; HeLa;
TD40
[17,18,94]
SR protein family HeLa; 293T HEK; TD40 [10,14,17,18]
Additional regulatory splicing factors HeLa; 293T HEK; TD40 [13–15,17,18]
hPRP19 complex HeLa; DT40 [17,18]
3′-end processing components HeLa; TD40 [17,18,39]
Cap binding proteins HeLa; 293T HEK; DT40 [17,18,39]
A-to-I RNA editing enzymes HeLa; 293T HEK; TD40 [17,43,95,96]
Microprocessor components HeLa [64]
mRNA export and surveillance
components
HeLa; TD40 [17,18]
RNA metabolism HeLa; TD40 [17,18]
Table 2
Nuclear RNAs associated with supraspliceosomes.
2a. pre-mRNA/mRNAs individually associated with supraspliceosomes
Pre-mRNA/mRNA Cells origin References
Poly(A) + nuclear RNA Syrian hamster [21]
CADa Syrian hamster [97]
DHFRa Syrian hamster [21]
ß-Actina Syrian hamster; HeLa [94]
Histone H4a Syrian hamster; HeLa [21]
AdML minigenea HeLa [18]
SMNa HeLa; HEK 293 [33]
ADAR 2a HeLa; HEK 293 [33]
hnRNP A/Ba HeLa; HEK 293 [33]
Tau minigenea HEK 293 [14]
HTR2C minigenea HEK 293 [57]
2b. U snRNAs associated with supraspliceosomes
U snRNA Cell origin References
U1 HeLa; Syrian hamster; TD40 [10–12,17–19,98]
U2 HEK 293; HeLa; Syrian
hamster; TD40
[10–12,17–19,87,98]
U4 HEK 293; HeLa
Syrian hamster; TD40
[10–12,17–19,87]
U5 HeLa; Syrian hamster; TD40 [10–12,17–19]
U6 HeLa; Syrian hamster; TD40 [10–12,17–19,98]
2c. Small non-coding RNAs associated with supraspliceosomesb
Small non-coding RNA Cell origin References
Initiator-tRNA HEK 293 [87]
Intronic pre-miRNAsc:
miR-762 (HTR2C)d HeLa [69]
miR-1912 (HTR2C)d HeLa [69]
miR-1264 (HTR2C)d HeLa [69]
miR-1298 (HTR2C)d HeLa [69]
miR-106b (MCM7)d HeLa [64]
miR-93 (MCM7)d HeLa [64]
miR-25 (MCM7)d HeLa [64]
miR-330 (EML2)d HeLa [64]
a Examples of pre-mRNA/mRNAseach individually associatedwith a supraspliceosome.
b A temporary list of small non-coding RNAs associated with supraspliceosomes.
c A list of published intronic pre-miRNAs found associated with supraspliceosomes.
d Host gene of intronic miRNA.
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Eukaryotic pre-mRNAs are transcribed by RNA Polymerase II (Pol II)
and have to undergo several processing events before they can exit from
the nucleus to the cytoplasm to encode for proteins. These processing
events include 5′ end and 3′ end processing, editing and splicing. In
the cell nucleus each mammalian pre-mRNA is assembled in a huge
nuclear ribonucleoprotein (RNP) complex – the supraspliceosome – in
which pre-mRNA processing most likely takes place.
Splicing of pre-mRNAs to remove the introns and ligate the exons is
a two-step transesteriﬁcation reaction that occurs within the highly
dynamic splicing machine. The accuracy and efﬁciency of pre-mRNA
splicing are attributed to a number of cis elements, such as the 5′ and
3′ splice sites (SS), a branch point, a polypyrimidine tract, and splicing
enhancers and silencers. These are recognized by transfactors, which
include the spliceosomal uridine-rich snRNPs (U1, U2, U4, U5 and U6
snRNPs) and several non-snRNP protein splicing factors, such as the
Serine/Arginine (SR) rich protein family and hnRNP proteins [1].
The U snRNPs are central components of the spliceosome. They
participate in splice-site recognition and have an essential function in
splicing through cooperative RNA:RNA interactions between the
snRNAs and the pre-mRNA [2–4]. Studies in vitro have shown that the
assembly of the spliceosome occurs in a stepwise manner (reviewed
in refs [2,4,5]), and involves an intricate series of interactions between
theﬁvemajor U snRNPs, aswell aswith a number of non-snRNP splicing
factors, which are dynamically recruited to the spliceosome when
an exogenous pre-mRNA is added to a nuclear extract. A number of
intermediate complexes were identiﬁed during the assembly of the
spliceosome in vitro [6]. First, U1 snRNP is bound to the 5′SS of the
pre-mRNA together with various proteins generating complex E. Next,
the entry of U2 snRNP deﬁnes the branch-point and leads to the forma-
tion of the A complex. Binding of the U4/U6.U5 tri-snRNP forms the pre-
catalytic B complex, that harbors the ﬁve-spliceosomal U snRNPs. This
step is followed bymajor rearrangements in RNA:RNA and RNA:protein
interactions, destabilization of U1 and U4 snRNPs and formation of
activated complex Bact. This is followed by generation of complex B*,
which catalyzed the ﬁrst step of splicing, generating complex C, which
catalyzes the second step of splicing. Thus, the splicing active complex
contains U2/U6.U5 snRNPs [1]. Studies of the structure and function of
the in vitro assembled spliceosome have been summarized in updated
reviews [1,7,8].
Here we focus on the structure and function of the splicing machine
isolated from the nuclei of mammalian cells — the supraspliceosome
(reviewed in ref. [9]). This machine is not only responsible for splicing
and splicing regulation in the cell nucleus, but also responsible for all
pre-mRNA processing activities mentioned above and more, as will be
discussed here.
2. The supraspliceosome
When isolated from cell nuclei, under physiological conditions,
mammalian pre-mRNAs are found packaged with all ﬁve spliceosomal
U snRNPs [10–12], and splicing factors [9–15] in huge (21MDa) [16] nu-
clear RNP particles — supraspliceosomes. Composition analyses
including mass spectrometry (MS) analysis (Table 1) of the general
population of supraspliceosomes isolated from cell nuclei [17], or of
afﬁnity puriﬁed supraspliceosomes assembled on a speciﬁc transcript
[18], reveled the presence of over hundred proteins, and conﬁrmed the
presence of all required splicing factors in supraspliceosomes [17,18].
Supraspliceosomes are composed of four splicing active substructures –
native spliceosomes – connected by the pre-mRNA [19]. Importantly,
the entire repertoires of nuclear pre-mRNAs, appear to be assembled in
splicing-active supraspliceosomes (Table 2b and reviewed in ref. [9]). A
remarkable feature of supraspliceosomes is that they individually package
a single pre-mRNA transcript each of different sizes and of different
numbers of introns (Table 2a) into complexes of a unique size andhydrodynamic properties, indicating their universal nature [10,11,
19–22]. The supraspliceosome structure provides a platform where
numerous regulatory processing steps that the pre-mRNA undergoes
occur [9], emphasizing the role of the supraspliceosome as a master
regulator of pre-mRNA processing. The question arises why is the nuclear
processing machine so complex? In the following sections we will detail
the characteristic of the supraspliceosome with the aim of trying to
elucidate this point.
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spliceosomal U SnRNPs during the steps of the splicing reaction
The U snRNPs are central components of the spliceosome. Studies
in vitro have shown that the assembly of the spliceosome occurs in
a stepwise manner with changes in U snRNP composition (reviewed
in refs. [2,4,5,8]). While a pre-catalytic complex involves the ﬁve
spliceosomal U snRNPs, the splicing active complex contains U2/U6.U5
snRNPs [1].
In contrast to these ﬁndings, Northern blot analysis (Table 2b)
revealed that the general population of supraspliceosomes harbors the
ﬁve-spliceosomal U snRNPs [10,12,19]. Also, native spliceosomes, the
subunits of the supraspliceosome, harbor all ﬁve spliceosomal U snRNAs
[19]. These ﬁndings are consistent with the ﬁnding of a functional
penta-snRNP in yeast [23].
The above studies represent averaged-characteristics of the
supraspliceosome as they dealt with the steady state population of Pol
II transcripts that differ in their number of introns and exons, and in
their stage of the splicing reaction. We recently analyzed the U snRNP
composition of afﬁnity puriﬁed speciﬁc supraspliceosomes assembled
on speciﬁc transcripts at deﬁned functional states [18]. We used the
Pseudomonas aeruginosa phage 7 (PP7) RNA binding site/recombinant
PP7 coat protein (PP7CP) system [24], to afﬁnity purify PP7-tagged
splicing complexes [18]. A series of stable cell lines was prepared
(Fig. 1A, B), each expressing a PP7-tagged wild type (WT), or mutant
(Mut) AdML, having a mutation at the 3′SS that inhibits the second
step of splicing, and having the PP7-tag either at the 3′ UTR or at the
intron. We also prepared control cell lines lacking the PP7 tag. SpeciﬁcFig. 1. The ﬁve-spliceosomal U snRNAs are associatedwith in vivo assembled supraspliceosome
line from which speciﬁc supraspliceosomes at deﬁned splicing stages were afﬁnity puriﬁed usin
lacking tag were used as controls. Open boxes represent exons, lines represent introns, and st
expressing AdML-WT. (B) Constructs expressing AdML-Mut, having a mutated 3′ splice site, de
U snRNAs was performed on RNA extracted from nuclear supernatants (Nuc. Sup.), and from a
AdML constructs either with the PP7 tag or without it (−), as indicated. AdML-WT suprasplic
found assembled on pre-mRNA [18]. Left, the AdML-WT-PP73′UTR supraspliceosome
supraspliceosomes. The identity of the U snRNA probes is given on the left.
Adapted from Kotzer-Nevo et al. [18].afﬁnity puriﬁcation of the AdML assembled complexes from each of
the cell lines expressing PP7-tagged AdML was achieved, and revealed
that they were assembled in supraspliceosomes [18]. AdML-WT
supraspliceosomes were found assembled on mature RNA, and AdML
Mut supraspliceosomes were found assembled on pre-mRNA. Northern
blot analysis using probes for the ﬁve spliceosomal U snRNAs revealed
that all ﬁve spliceosomal U snRNAs are associated with each of
the above afﬁnity-puriﬁed AdML supraspliceosomes: AdML-WT-PP73′
UTR supraspliceosomes that are assembled on mature mRNA (Fig. 1C,
lane 2); as well as on AdML-Mut-PP73′UTR and AdML-Mut-PP7IVS
supraspliceosomes that are assembled on AdML pre-mRNA (lanes 6
and 10, respectively) [18]. Very low levels of U snRNAs were found
in the control samples that lack the PP7 tag (lanes 4, 8, and 12),
with some non-speciﬁc binding of U1 snRNA, which is known to be in
excess in the cell nucleus [25]. It can therefore be concluded that
supraspliceosomes isolated from mammalian cell nuclei have all ﬁve
spliceosomal U snRNAs associated with them at all splicing stages.
These ﬁndings highlight the important role of large, pre-formed,
complexes in pre-mRNA splicing in vivo.
The apparent discrepancy between a stepwise assembly pathway of
the spliceosome in vitro and the occurrence of a pre-formed splicing
complex in vivo, has been explained by a “holospliceosome” model, in
which the sequential complexes represent ordered modulations within
the in vivo assembled spliceosome without the loss of components [4]. It
has also been pointed out that such intermediate states in spliceosome
assembly in vitro may not occur in vivo [23,26].
While the assembly pathways of supraspliceosomes in vivo occur in
the nucleus co-transcriptionally, that of spliceosomes assembled in vitros at all splicing stages. (A, B) Schemes of AdMLminigenes, each expressed from a stable cell
g the PP7/PP7CP system [24]. Stable cell lines expressing the respective AdML transcripts
em-loops represent the PP7 tag inserted either at the 3′UTR or the intron. (A) Constructs
signated “x”. (C) Northern blot analysis with probes directed against the ﬁve-spliceosomal
fﬁnity puriﬁed supraspliceosomes (Elution), prepared from HeLa cell-lines expressing the
eosomes were found assembled on mature RNA, and AdML Mut supraspliceosomes were
s; middle, the AdML-Mut-PP73′UTR supraspliceosomes; Right, AdML-Mut-PP7IVS
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components present in a nuclear extract. These two pathways may lead
to different local minima in the respective free energy proﬁles, which
may result in the assembly of slightly different complexes. Alternatively,
the observed changes in composition between intermediate complexes
assembled in vitro, which are not found in supraspliceosomes assem-
bled in vivo, may be due to the lack of speciﬁc components in the
in vitro assembled complexes, which might help keep the in vivo
assembled complexes intact.
2.2. Supraspliceosome structure
The complexity and large size of the supraspliceosome make EM
the method of choice for its structural analysis. 3-D image recon-
struction of individual supraspliceosomes by automated electron to-
mography of negatively stained [20,27], and of frozen hydrated
complexes [28] showed the supraspliceosome as forming a closed
structure, 50 × 50 × 35 nm in dimensions, composed mainly of four
similar native spliceosomes.Massmeasurements by scanning transmis-
sion EM (STEM) showed that the supraspliceosome has a mass of
21 MDa, whereas each of the native spliceosomes has a mass of
4.8 MDa [16]. Notably, when the dynamics of U1 snRNPs within live
cells was analyzed at the single-particle level [29], most U1 snRNPs
were found bound to speciﬁc intranuclear sites, many of those presum-
ably representing sites of pre-mRNA splicing. The dissociation kinetics
from these sites reﬂects the involvement of U1 snRNP in numerous dis-
tinct interactions. Mobile U1 snRNPs moved with diffusion constants in
the range of 0.5–8 μm2/s, values that are consistent with uncomplexed
U1 snRNPs diffusing at a viscosity of 5 cPoise and U1 snRNPs moving
in a largely restricted manner, and U1 snRNPs contained in large supra-
molecular assemblies such as spliceosomes or supraspliceosomes, dif-
fusing in a hindered manner through the nucleoplasm [29].
The relatively uniform mass of the supraspliceosome (21.1 ±
1.6 MDa; n = 400) [16], likely reﬂects the presence of a general basic
structure. Using a positive staining protocol, which allowed visualiza-
tion of nucleic acids, we could show strands and loops of RNA emanat-
ing from positively stained supraspliceosomes [16] (see Fig. 3C),
indicating that the RNA is loosely bound and therefore accessible for
probing. Furthermore, ﬁbers, presumably the pre-mRNA covered with
proteins, through which the native spliceosomes are interconnected
were observed by 2-D image restoration of ice-embedded particles
[28]. These observations support our working hypothesis that the
native spliceosomes are connected by the pre-mRNA. Within the
supraspliceosome, the native spliceosomes are arranged such that
their small subunits reside in its center. This conﬁguration allows com-
munication between the native spliceosomes [30].
The four substructures of the supraspliceosome are interconnected
in a ﬂexible way and may thus adopt different angular settings, which
impose a signiﬁcant restriction on reaching high resolution in EM
image analyses. We have therefore developed a methodology to isolate
the native spliceosomes from supraspliceosomes, by speciﬁc cleavage of
the general population of pre-mRNAs, while keeping the snRNAswithin
these substructures intact [19]. The 3-D structure of the native
spliceosome was determined by the cryo-EM single particle technique
at a resolution of 20 Å, and revealed an elongated globular particle com-
posed of a large and a small subunit (Fig. 2A–C) [31]. The two subunits
are interconnected to each other leaving a tunnel in between, which is
large enough to allow the pre-mRNA to pass through (Fig. 2A). The
other side of the native spliceosome exposes a cavity that could provide
a place to transiently store the labile pre-mRNA and protect the part
of the pre-mRNA that is not directly involved in the splicing reaction
from non-speciﬁc degradation (Fig. 2B). Because RNA is denser than
protein, high-density regions can provide some information about its
internal localization. The large subunit was thus proposed as a suitable
candidate to accommodate the ﬁve spliceosomal U snRNPs, as the
high density regions were found there (Fig. 2C) [31].Support for this suggestion, comes from our recent analysis of the
localization of U snRNPs within the native spliceosome, using a new
computational procedure we designed to efﬁciently ﬁt thousands of
conformers into the spliceosome envelope. Despite the low-resolution
limitations, a unique spatial arrangement of the spliceosomal U snRNPs
within the native spliceosome emerged from our in-silico studies
(Fig. 2D). Our model localizes the ﬁve U snRNPs mostly within the
large subunit of the native spliceosome, requiring onlyminor conforma-
tion changes. The remaining free volume presumably accommodates
additional spliceosomal components. The constituents of the active
core of the spliceosome are juxtaposed, forming a continuous surface
deep within the large spliceosomal cavity, which provides a sheltered
environment for the splicing reaction [32].
3. The supraspliceosome model
In the proposed model (Fig. 3), the supraspliceosome represents a
stand-alone complete macromolecular machine capable of performing
splicing of every pre-mRNA — irrespective of its length or the number
of introns it contains. It presents a closed-structure-model composed
of four native spliceosomes connected by a single pre-mRNA. Critical ex-
perimental support of this model comes from experiments, which
showed that cleavage of the pre-mRNA yielded functional native
spliceosomes that could be reconstituted into supraspliceosomes by in-
cubation with exogenously added pre-mRNAs [19,31]. The hypothesis
that each supraspliceosome is assembled on a single pre-mRNA was
veriﬁed by EM visualization of supraspliceosomes reconstituted from
native spliceosomes and from pre-mRNA tagged at its 3′ end with one
Nanogold particle (1.4 nm) [33]. The supraspliceosome structure pro-
vides a platform to juxtapose exons about to be spliced, and each of
the four native spliceosomes, resembling an in vitro assembled
spliceosome, can splice the intron wound around it (Fig. 3). In this con-
ﬁguration the supraspliceosome acts as a multiprocessor machine that
can simultaneously splice four introns—not necessarily in a consecutive
manner.
In this schematic model, each of the native spliceosomes is presented
by the 20-Å resolution structure of the native spliceosome [31]. The small
subunit of each native spliceosome, proposed to harbor non-snRNP com-
ponents such as SR proteins and hnRNP proteins, is placed at the center of
the supraspliceosome [30]. This conﬁguration allows communication be-
tween the native spliceosomes, which is a crucial element for regulated
alternative splicing and for quality control of the resulting mRNAs. This
setting places the large subunit of each native spliceosome, where cataly-
sis by the U snRNPs presumably takes place, in the periphery of the
supraspliceosome. This localization of the U snRNPs within the native
spliceosome was recently supported by our in-silico study showing
unique localization of the U snRNPs within the native spliceosome [32].
Thus, the supraspliceosome presents a platform onwhich splice junctions
could be checked prior to intron excision. An attractive feature of such a
machine is that it allows rearrangement of splice junction combinations
to select the appropriate ones. This way it comprises an important tool
to ensure the ﬁdelity of splicing and alternative splicing.
Splicing of amulti-intronic pre-mRNA can be facilitated by the trans-
location of the pre-mRNA through the complex in a ‘rolling model’
fashion. After processing four introns the RNA roles in to place a new
subset of introns in the correct position for processing. Cotranscriptional
splicing [34–36] may help explain how pre-mRNAs having an excep-
tionally large number of introns (e.g. dystrophin or CAD) can be spliced
by the supraspliceosome in a rolling mode. At the other extreme,
both reconstitution experiments with pre-mRNAs having only
one intron [19], and afﬁnity puriﬁcation of supraspliceosomes
assembled on PP7-tagged AdML transcripts with one intron [18],
revealed that pre-mRNAs having less then four introns are also
packaged in supraspliceosomes. Thus, the interactions of the RNA
with the native spliceosomes per se are presumably sufﬁcient to
hold the structure together.
Fig. 2. Structure of the native spliceosome. (A, B) Two different views of the structure of the native spliceosome reconstructed at 20 Å resolution from cryo-images [31]. (C) The high-density
mass region of the native spliceosome (red) represents the stable RNAswithin the structure of the native spliceosome. The large subunit of the native spliceosome is thus a suitable candidate to
harbor theﬁve-spliceosomalU snRNPs. Adapted fromAzubel et al. [31]. (D) Aunique spatial arrangement of theU snRNPswithin the native spliceosome emerges from in-silico studies [32]. The
native spliceosome is transparent; U4/U6.U5 tri-snRNP is colored by functional regions,withU5 snRNP in pink and the region attributed to loop I in black [93]; U4/U6 in beige-orange; U2 snRNP
subcomponent SF3b is in green; and U1 snRNP is blue. Adapted from Frankenstein et al. [32].
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4.1. Splicing
Wehave shown that both native spliceosomes and supraspliceosomes
are active in splicing [19,31]. This was shown by complementing splicingFig. 3. The supraspliceosome model. (A, B) Schematic models of the supraspliceosome in which
supraspliceosome presents a platform onto which the exons can be aligned and splice junctions ca
and protectedwithin the cavities of the native spliceosome. (B, C)When a staining protocol that all
seen emanating from the supraspliceosomes [16]. (B) Under these conditions the RNA kept in th
depicted in theupper left corner. Adapted fromAzubel et al. [19]. (C) STEMdarkﬁeld images of sup
fromMuller et al. [16]. Bar represents 10 nm.activity of amicrococcal nuclease treatedHeLa nuclear extract, whichwas
inactive in splicing. We have further shown that this splicing activity
could be attributed to the native spliceosomes and not to the U snRNAs
or U snRNPs they contain. Support for the functional signiﬁcance of
supraspliceosomes was provided from a study showing that U2/U6
snRNA base pairing, which characterizes active spliceosomes assembledthe pre-mRNA (introns in blue, exons in red) is connecting four native spliceosomes. The
n be checked before splicing occurs. (A) The pre-mRNA that is not being processed is folded
ows visualization of nucleic acidswas used, RNA strands and loops boundwith proteinswere
e cavity is proposed to unfold and loop-out. In the looped-out scheme an alternative exon is
raspliceosomes [16] stainedwith a protocol that allows visualization of nucleic acids. Adapted
118 K. Shefer et al. / Computational and Structural Biotechnology Journal 11 (2014) 113–122in vitro, was found in complexes sedimenting between 150-300S but not
in 60S complexes [37]. These studies are in support of the
supraspliceosome model, in which the native spliceosomes within the
supraspliceosome are active in splicing.
4.2. Pre-mRNA processing activities: 5′ end, 3′ end processing and editing
Transcripts of Pol II have to undergo several processing steps before
they can exit from the nucleus to the cytoplasm to encode for proteins.
These activities include, in addition to splicing, 5′ end and 3′ end
processing, and RNA editing. Since Pol II transcripts are assembled in
supraspliceosomes from the transcription site until they reach the
nuclear pore for export from the nucleus to the cytoplasm [38], we
asked if components of the additional processing activities are present
in supraspliceosome. We showed that the cap-binding proteins
(CBPs), CBP20 and CBP80 are associated with supraspliceosomes
(Table 1), and so are components of 3′ end processing [39]. These ﬁnd-
ings were conﬁrmed my MS analyses [17,18].
The ADAR (adenosine deaminases acting on RNA) editing enzymes
act on double stranded RNA and convert A-to-I. Because inosines are
recognized by the splicing and translation machineries as guanosines,
RNA editing in coding regions or in introns can change the codons, or
splicing patterns, respectively [40–42]. The involvement of introns in
editing, either as substrates for editing or as part of the complementary
strand of the RNA duplex, suggested that A-to-I editing is likely to occur
in supraspliceosomes. Accordingly, we have shown that the editing
enzymes ADAR1 and ADAR2 are associated with supraspliceosomes
(Table 1), and that they are enzymatically active [43]. These ﬁndings
were conﬁrmed my MS analyses [17,18].
4.3. Alternative splicing
Alternative splicing (AS) is a major source of the diversity of the
human proteome and plays a major role in the regulation of gene
expression. It is estimated that the majority of human genes undergo
regulated AS [44–47]. Importantly, alterations in AS and misregulation
of factors affecting AS were shown to be involved in several human
diseases, including cancer [48–51].
Regulated splicing, as well as constitutive splicing, operates through
the combinatorial interplay of positive and negative regulatory signals
present in the pre-mRNA, which are recognized by trans-acting factors.
Themost studied of the latter aremembers of the hnRNP [52,53] and SR
protein families [54–56]. The high ﬁdelity of exon recognition is thus
achieved by the combination of multiple weak protein:protein, pro-
tein:RNA and RNA:RNA interactions.
Because the entire repertoire of nuclear pre-mRNAs is individually
found assembled in supraspliceosomes, we asked if the ability to
perform alternative splicing is an integral part of the in vivo splicing
machine. The tetrameric structure of the supraspliceosome, in which
four native spliceosomes are connected by the pre-mRNA, suggests
that such amulti-subunit structurewas designed to coordinatemultiple
processing events, such as alternative splicing. In accordance with this
suggestion, we have shown that the supraspliceosome contains splicing
regulatory proteins as integral components (Table 1). The list includes
the splicing regulators RBM4 and Wilm's tumor protein 1 (WT1) [13],
the alternative splicing regulator ZRANB2 [15], and the splicing regula-
tory proteins belonging to the SR proteins family [10,39], and hnRNP G
[14], which are predominantly found in supraspliceosomes, as well as
additional splicing regulators identiﬁed by MS of afﬁnity puriﬁed
supraspliceosomes [18]. The association of regulatory splicing factors
with supraspliceosomes is in support of their proposed role in splicing
regulation and alternative splicing.
Importantly, the supraspliceosome was shown as the nuclear com-
plex in which alternative splicing is regulated. First, hnRNP G was
shown to affect the alternative splicing of the tau pre-mRNA transcript
in supraspliceosomes [14]. Furthermore, both the constitutively andalternatively spliced mRNAs of the endogenous human pol II transcripts:
hnRNP A/B, survival of motor neuron (SMN) and ADAR2 are predomi-
nantly found in supraspliceosomes. Notably, overexpression of SRSF5
(SRp40) enhanced exon 7 skipping in supraspliceosomes assembled on
hnRNP A/B transcripts, while treatment with C6-ceramide was accompa-
nied with exon 7 inclusion in hnRNP A/B supraspliceosomes [33].
Additional studied case is the regulation of alternative splicing
of the serotonin receptor 2C (HTR2C) transcripts that occur in
supraspliceosomes. A recent screen for substances that promote produc-
tion of active HTR2C, through alternative splicing including exon5b, iden-
tiﬁed pyrvinium pamoate as a drug promoting exon 5b inclusion [57].
We have shown that the HTR2C mRNA is found in supraspliceosomes.
Importantly, addition of pyrvinium pamoate resulted in increase in exon
5b inclusion within the supraspliceosome fractions [57]. These ﬁndings
support the proposed role of the supraspliceosome in splicing regulation
and alternative splicing.
4.4. Intronic miRNA processing in supraspliceosomes
MicroRNAs (miRNAs) are small ~22 nt long molecules involved in
the negative control of gene expression by binding mainly to the 3′
UTR of target mRNA transcripts. Notably, a large fraction of miRNA
genes are located in introns. The canonical biogenesis of intronic
miRNAs from Pol II transcripts involves two main steps: First, cleavage
of the primary (pri) miRNA transcript into a precursor (pre) miRNA
stem-loop molecule of about 70–80 bases by the microprocessor in
the nucleus. Second, after export to the cytoplasm, the pre-miRNA is
cleaved by Dicer yielding mature miRNA, which loaded on the RNA
Induced Silencing Complex (RISC) binds to its target gene [58–63].
Since a large proportion of miRNA genes are located in introns, we
asked whether there is a cross-talk between their processing and pre-
mRNA splicing within the in vivo pre-mRNA processing machine. In a
recent study [64], we showed that the main microprocessor compo-
nents, Drosha and DGCR8 are found in supraspliceosomes (Table 1).
We further showed that inhibition of splicing increases miRNA expres-
sion,while knock-down of Drosha increases splicing. In order to analyze
the processing of speciﬁc miRNAs, we focused on the miR-106b-25
cluster (miRNAs 106b, 93 and 25), which is conserved in mammals
and is pro-oncogenic [65]. The miR-106b-25 cluster is harbored in in-
tron 13 of MCM7 (minichromosome maintenance 7) [62,66], which
plays a critical role in the G1/S phase transition, ensuring that all the ge-
nome is only replicated once at each cell cycle [65]. RT-PCR analysis re-
vealed that pri-miR 25 is found in supraspliceosomes. Furthermore,
deep sequencing of small RNA (b200 nt) from supraspliceosomes re-
vealed the presence of pre-miRNA 106b, pre-miRNA 93 and pre-
miRNA 25 (Table 2c). This study showed that both the pri-miRNAs
and the pre-miRNAs of the miR-106b-25 cluster are found in
supraspliceosomes [64]. These ﬁndings bring further support to the
cross-talk between the splicing and miRNA processing machines and to
the hypothesis that the processing of the tested intronic miRNAs occurs
in supraspliceosomes [64]. Earlier ﬁndings of association between certain
splicing components and themicroprocessor and pre-miRNAs [67,68] are
in support of our ﬁndings.
An additional interplay between splicing andmiRNA processingwas
unraveledwhenwe identiﬁed a novel alternative 3′ splicing event in in-
tron 13 of MCM7, between pre-miRNAs 93 and 25, which occurred at a
highly conserved 3′SS sequence. Importantly, the new splice isoform in-
corporates the sequence of pre-miR-25 into exon 14 of MCM7. While
both miRNA 25 and MCM7 mRNA can be generated from the same
MCM7 pre-mRNA, when spliced at the normal SS, this is not the case
when splicing occurs at the novel 3′SS. Splicing at this novel 3′SS ex-
cludes processing of pri-miRNA-25 into miR-25, affecting its biogenesis,
and at the same time generates a new isoform of MCM7 mRNA, which
encodes for a shortened protein that lacks the 3′ carboxy terminus.
Thus, the expression of the novel splice isoform affects the levels of
the different miRNAs of the cluster and also affects the splice isoforms
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shows a cross-talk and competition between splicing and miRNA bio-
genesis, which might also differentially affect the levels of clustered
intronic miRNAs [64].
Among RNA sequences, found in deep sequencing of small RNAs
from supraspliceosomes isolated fromnuclei of HeLa cells, we identiﬁed
sequences of pre-miRNAs of miR-764, miR-1260, miR-1912 and miR-
1298 (Table 2c and Ref. [69]). These miRNAs are encoded in intron 2
of the serotonin receptor 2C (HTR2C), known to be exclusively
expressed in neurons [70]. This observation led to the ﬁnding that
HTR2C, which encodes for a G-protein coupled receptor, has an addi-
tional transcript coming from the 5′ untranslated region of the receptor,
and this pre-mRNA aswell as its hostedmiRNAs arewidely expressed in
non-neuronal cell lines. This is an additional example of cross talk
between the supraspliceosome and the processing of microRNA [69].
Furthermore, the presence of both pri-miRNAs and pre-miRNAs in
supraspliceosomes [64,69] suggests that this nuclear processing step
likely occurs in supraspliceosomes.
4.5. Stop codon-mediated suppression of splicing— SOS
A key step in pre-mRNA splicing involves the recognition and selec-
tion of a consensus sequence (AG/GTRAGT; in mammals, where R de-
notes purine and “/” denotes the splice junction) that deﬁnes the 5′SS
[71]. An estimate based on alignment of EST data showed that splicing
involving alternative 5′SSs account to about 8% of the total alternative
splicing events that are conserved between the human and the mouse
genomes [72]. This fraction, however, is much smaller than that expect-
ed from sequence alone. We found that over 70% of the introns within
the coding regions of human genes harbor multiple sequences that
comply with the 5′SS consensus (on average 9.19 sequences/intron
[73]), but these sequences are not used for splicing (latent 5′SSs).
Importantly, the intronic sequences upstream of almost all of these
sites (N98%) harbor at least one in-frame stop codon and therefore
has the potential of introducing premature termination codons (PTCs)
into the alternatively spliced isoform [73]. mRNAs that contain PTCs
(nonsense mRNAs) might be toxic to cells as they code for truncated
nonfunctional proteins that could have a deleterious dominant negative
effect on the cell's metabolism [74–76].
The presence of such a large number of latent 5′SS raises the
question: why splicing at latent 5′SSs (latent splicing) has not been de-
tected under normal growth conditions? In principle, two scenarios can
account for this phenomenon (Fig. 4A): (i) Splicing at latent 5′SSs does
occur, but the nonsense mRNAs thus formed are rapidly and efﬁciently
degraded, by any RNA surveillancemechanism (e.g., NMD) [74–78] to a
level below detection; and (ii) Splicing events at intronic 5′SSs that are
preceded by at least one stop codon in frame with the upstream exon
are suppressed. We have tested the ﬁrst scenario in a substantial
number of independent experiments: It was thus shown that SOS was
not affected (i.e. latent splicing was not elicited in the tested gene tran-
scripts) upon abrogation or bypassing theNMDpathwayby a number of
ways: Inhibition of translation [79–81] and, in particular, inhibition of
the pioneer round of translation, which had been shown to be essential
for NMD [82], by expressing a dominant negativemutant of the transla-
tion initiation factor eIF2-α, did not elicit latent splicing [81]. Further-
more, RNAi of the NMD genes hUpf1 and hUpf2, or the expression of
three mutants of hUpf1 that abrogated NMD [83], did not elicit latent
splicing [80]. Because Upf1 is essential for mammalian NMD [84–86],
these data do not ﬁt a model that could attribute the lack of latent
splicing to a rapid and complete degradation of latent mRNAs by
NMD. We also ruled out degradation of latent mRNA by a yet unknown
RNA degradation mechanism by showing that constructs in which we
forced formation of latentmRNA, through its expression from a plasmid
harboring the already spliced DNA, express latent mRNA at levels only
slightly lower than the level of authentic mRNA expressed from a
plasmid harboring the already spliced DNA at the authentic 5′SS [87].On the other hand, the data summarized above, ﬁt the second scenario
and invoke a mechanism termed suppression of splicing (SOS) that
suppresses splicing involving latent alternative 5′SSs whose usage
could introduce an intronic stop codon into the resultant mRNA [88].
Supporting evidence for the idea that PTC-harboring pre-mRNAs can
be recognized in the cell nucleus, resulting in suppression of splicing has
also been provided in a number of studies [89–92], including a recent
study showing that un-spliced PTC-harboring transcripts are retained
at nuclear transcription sites [92].
Latent 5′SSs are indeed legitimate and functional as has been shown
by eliciting latent splicing in three different ways. First, by eliminating
the stop codons (in several gene constructs) either by point mutations
that converted the stop codons to sense codons or by frame shifting
through the insertion (or deletion) of nucleotides upstream of the
stop codons [79,80]. Second, by disrupting the reading frame through
mutations made in the start ATG codon [81,87]. Third, by subjecting
cells to stress conditions, such as heat-shock, hypoxia, or treatment
with certain antibiotics [22,73,80,81], or in cancer cells, where activa-
tion of latent splicing was recently found in thousands of gene tran-
scripts expressed in breast cancer cells and in gliomas [73].
It has been shown that AUG sequences are essential for SOS, while
protein synthesis is not required. Mutations in the translation initiation
codon (AUG) elicited latent splicing — even though the stop codons
remained intact [81]. This ﬁnding indicated that maintenance of an
open reading frame is required to sustain SOS, and suggested a role in
SOS for the initiator-tRNA. Indeed, we have shown that this molecule
may also act, in amanner that is independent of its role in protein trans-
lation, as a pre-mRNA splicing regulator. Speciﬁcally, we showed that
activation of latent splicing, induced bymutations in the translation ini-
tiation AUG codon, could be suppressed by expressing initiator-tRNA
constructs carrying anticodon mutations that compensate for the AUG
mutations [87]. Importantly, the initiator-tRNA species proposed to
participate in SOS reside in the cell nucleus, are found associated with
supraspliceosomes (Table 2c), and appear not to be charged with an
amino acid [87].
For the mechanism of SOS we have proposed a working model,
based on what is known on the splicing mechanism and on our pub-
lished observations, and termed it sense triplet-recognition mechanism
that can be interrupted by stop codon-binding proteins (Fig. 4B). As its
name implies, this mechanism is based on three elements. First, as
already shown [87], the AUG sequence is recognized by the comple-
mentary anticodon (UAC) of the initiator-tRNA, probably in a complex
with auxiliary proteins. This step is proposed to recruit the SOS mecha-
nism and helps establish a register for the recognition of the reading
frame. We next hypothesized that this step involves the cooperative
polymerization of a protein(s) that bind triplets of nucleotides and in
the lack of PTC constitutes the “approval” step of splice site selection
that triggers the remodeling of the spliceosome to its functional state.
The latter step is interfered in the presence of a PTC, perhaps through
a competing interaction with a stop-codon-binding protein (e.g. a re-
lease factor-like protein). The unproductive complex may undergo a
conformational change and revert to the productive splicing complex
involving the authentic 5′SS, as indicated by the double arrows (see
Fig. 4B).
The association of initiator-tRNA with the supraspliceosome
suggests that the SOS mechanism, is likely incorporated as part of the
splicing machine and may thus act as a quality control mechanism
that scans along exons, avoiding the looped out introns and ensures
the production of a translatable mRNA.
5. Summary and outlook
In the cell nucleus, mammalian transcripts of Pol II are assembled in
supraspliceosomes (reviewed in ref [9]) and have to undergo several
processing modiﬁcations before they can exit from the nucleus to the
cytoplasm to encode for proteins. In addition to the 5′ end, and 3′ end
Fig. 4. Suppression of splicing (SOS). (A) A scheme depicting the two scenarios that can account for lack of latent splicing under normal growth conditions, despite the abundance of latent
5′SS sequences in introns. As discussed,we have ruled out the 1st scenario [79–81,87]. Boxes, exons; narrow boxes, latent exons; lines, introns; red octagon, stop codon. (B, C) A schematic
model for the quality control function of SOS. (B) Left scheme, splicing at the authentic 5′SS; right column, splicing at the latent 5′SS. (C) Splicing at the latent 5′SS after elimination of the in
frame stop codon. Blue stripes, exons; black line, intron; green narrow stripe, latent exon; red octagon, stop codon; circles, U snRNPs; orange ellipse (UAC), hypothesized AUG-binding
complex of initiator-tRNA; orange triangles, hypothesized triplet-binding proteins; red triangle, stop-codon-binding protein.
Adapted from Kamhi et al. [87].
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intronic and thus undergo alternative splicing. Furthermore, a large
fraction of mammalian introns harbor small non-coding RNAs, (e.g.
microRNAs), and thus their processing should be coordinated with the
other pre-mRNA processing activities. As summarized here, all these
processing activities: 5′ and 3′ endprocessing; RNAediting; constitutive
splicing; alternative splicing; and intronic microRNA processing, occur
in supraspliceosomes, the nuclear pre-mRNA processing machine.
Furthermore, since each transcript is subjected to a large number
of processing activities, which are sometimes complementary, yet,sometimes competitive, the nuclear pre-mRNA processing machine
should harbor also a quality control mechanism to coordinate all
these processing activities and to ensure the production of a “meaning-
ful” translatable mRNA. The SOS mechanism, which is part of the
supraspliceosome provides for such quality control. The requirements
for a quality control mechanism clarify also the question why the
supraspliceosome is composed ofmultiple spliceosomes. A splicingma-
chine composed of multi-spliceosomes enables coordinated processing
of a number of spliceosomes (e.g. alternative splicing), so that the
quality of the mRNA can be assessed before splicing, and only “correct
121K. Shefer et al. / Computational and Structural Biotechnology Journal 11 (2014) 113–122combinations” of splice junction are approved. When “wrong combina-
tions” of splice junctions are presented to the splicing machine, the qual-
ity control mechanism will not conﬁrm such a combination and the
unproductive complex may undergo a conformational change and revert
to the productive splicing complex. The fact that the supraspliceosome is a
closed structure in which the small subunits are placed in the center
might explain why the supraspliceosome is composed of four subunits
connected by the pre-mRNA. Because this structure enables close contact
between the small subunits, which is likely required for coordinated
processing of the pre-mRNA.
Introns of mammalian Pol II transcripts are long, and some of these
intronic sequences encode for miRNAs, which are processed in
supraspliceosomes, as discussedhere. It is likely that these large intronic
sequences may also host additional non-coding RNAs that are likely
processed within supraspliceosomes. Thus further analyses of the
supraspliceosomemight help elucidate the processing of novel intronic
small non-coding RNAs. Future structural and functional studies are re-
quired to decipher how all these processing activities are orchestrated
within this giant nuclear pre-mRNA processing machine, and what
changes and defects to this machine occur in disease.
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